. Author manuscript; available in PMC: 2018 Jan 17.

Published in final edited form as: J Bone Miner Res. 2009 Jul;24(7):1308–1313. doi: 10.1359/jbmr.090209

TABLE 2.

Least-Squares Mean Differences in the Percentage Change in Total Hip and Femoral Neck BMD Over Placebo in Patients Dosed ≤6 vs. >6 wk After Surgical Hip Fracture Repair

	12 mo (95% CI)	N	24 mo (95% CI)	N	36 mo (95% CI)	N
Total hip BMD (%)^*
≤6 wk	2.92 (1.94, 3.89)	604	5.29 (3.61, 6.97)	381	5.88 (3.38, 8.39)	157
>6 wk	4.19 (3.32, 5.06)	759	5.54 (3.94, 7.13)	424	7.64 (4.38, 10.89)	95
Femoral neck BMD (%)^*
≤6 wk	0.57 (−0.57, 1.72)	608	3.83 (2.10, 5.55)	387	2.27 (−0.66, 5.20)	156
>6 wk	3.88 (2.90, 4.87)	826	4.69 (3.11, 6.27)	464	7.86(4.11, 11.62)	97

N reflects total number of patients in the zoledronic acid and placebo groups combined.

For all CIs that exclude 0, level of significance is <0.0001.